Q-omics provides the consensus-scored HOXC13 profile across patient tissues and cancer cell-line models. HOXC13 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HOXC13 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, HOXC13 RNA expression shows 13,665 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where HOXC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXC13 survival associations across molecular data types. HOXC13 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXC13 RNA expression–survival associations across cancer types. High HOXC13 expression shows unfavorable associations in ACC, COAD, HNSC, KIRP, THCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HOXC13 RNA expression.
This table summarizes HOXC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HOXC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXC13 shows higher tumor expression in HNSC, LUSC, BLCA, LUAD, KIRC and BRCA. The HNSC box plot shows higher HOXC13 RNA expression in tumor versus normal tissue (log2 FC = +3.073, t-test p < 0.001).
This table shows molecular features associated with HOXC13 in patient tissues and cancer cell lines. In patient samples, HOXC13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
